Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,260 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: I-START Clear all
Active, not recruiting Phase 3 Interventional

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

NCT00978458
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neurotoxicity
Interventions
temozolomide, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
168
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 117 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 30, 2026, 6:29 AM EDT
Completed Phase 1 Interventional Results available

TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)

NCT02043847
View directory record Official record
Conditions
Multiple Myeloma, Relapsed, Multiple Myeloma, Refractory to Standard Treatment
Interventions
Total Marrow Irradiation, Melphalan, Filgrastim (G-CSF), Autologous transplant
Radiation · Drug · Procedure
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 30, 2026, 6:29 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

NCT02158091
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
IPI-145, Fludarabine, Cyclophosphamide, Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 30, 2026, 6:29 AM EDT
Recruiting Phase 1Phase 2 Interventional

Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients

NCT05074290
View directory record Official record
Conditions
Breast Cancer
Interventions
Epidiferphane, Taxane Chemotherapy
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 30, 2026, 6:29 AM EDT
Completed Phase 1 Interventional

Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

NCT01721525
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Cancer
Interventions
Afatinib, Ribavirin, and weekly carboplatin/paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Basking Ridge, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 30, 2026, 6:29 AM EDT
Completed Phase 1 Interventional

Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer

NCT01292668
View directory record Official record
Conditions
Basal Cell Carcinoma of the Skin, Pain, Recurrent Skin Cancer
Interventions
methyl-5-aminolevulinate hydrochloride cream, photodynamic therapy, laser therapy
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Oct 30, 2026, 6:29 AM EDT
Completed Phase 3 Interventional Results available

Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer

NCT01414608
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7
Interventions
Brachytherapy, Carboplatin, Cisplatin, External Beam Radiation Therapy, Paclitaxel, Quality-of-Life Assessment
Radiation · Drug · Other
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
926 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
315
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 220 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 30, 2026, 6:29 AM EDT
Completed Phase 3 Interventional

Medroxyprogesterone Compared With Venlafaxine in Treating Hot Flashes in Women

NCT00030914
View directory record Official record
Conditions
Hot Flashes
Interventions
medroxyprogesterone, venlafaxine
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
22
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 30, 2026, 6:29 AM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

NCT02364609
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Afatinib Dimaleate, Pembrolizumab
Drug · Biological
Lead sponsor
Jonathan Riess
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 30, 2026, 6:29 AM EDT
Completed Phase 1 Interventional Results available

Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors

NCT00800345
View directory record Official record
Conditions
Gynecologic Tumors
Interventions
Oral Topotecan, Pazopanib
Drug
Lead sponsor
Vector Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 30, 2026, 6:29 AM EDT
Completed Phase 1 Interventional

Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C)

NCT02313857
View directory record Official record
Conditions
CMV Infections
Interventions
Viralym-C
Biological
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 30, 2026, 6:29 AM EDT
Completed Phase 1 Interventional Results available

Phase I Study of APX005M in Pediatric Central Nervous System Tumors

NCT03389802
View directory record Official record
Conditions
Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS), CNS Primary Tumor, Not Otherwise Specified (NOS), Ependymoma, Not Otherwise Specified (NOS), Diffuse Intrinsic Pontine Gliomas (DIPG), Medulloblastoma
Interventions
APX005M treatment for recurrent or refractory primary malignant CNS tumor patients, APX005M treatment for newly diagnosed DIPG patients
Biological
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
1 Year to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 30, 2026, 6:29 AM EDT
Completed Phase 1 Interventional

Sirolimus and Cetuximab in Advanced Malignancies

NCT00940381
View directory record Official record
Conditions
Advanced Cancer
Interventions
Sirolimus, Cetuximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 30, 2026, 6:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

NCT00436501
View directory record Official record
Conditions
Fallopian Tube Cancer, Malignant Tumor of Peritoneum, Recurrent Ovarian Epithelial Cancer
Interventions
docetaxel, ziv-aflibercept, laboratory biomarker analysis, pharmacological study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Houston, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 30, 2026, 6:29 AM EDT
Active, not recruiting Phase 1 Interventional

Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer

NCT04046575
View directory record Official record
Conditions
Esophagus Cancer, Esophageal Cancer, Cancer of the Esophagus
Interventions
Intensity Modulated Radiation Therapy, Carboplatin, MD Anderson Symptom Inventory (MDASI)-Plus module, EuroQol (EQ-5D), SF-12, MOS Social Support Measure, CES-D, Blood for ctDNA (optional), Blood for SCCA, Paclitaxel
Radiation · Drug · Other + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 30, 2026, 6:29 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT00003311
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, methotrexate, vincristine sulfate
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 30, 2026, 6:29 AM EDT
Completed Phase 1 Interventional

Gemcitabine and Dasatinib in Advanced Solid Tumors

NCT00429234
View directory record Official record
Conditions
Advanced Cancer, Solid Tumors
Interventions
Dasatinib, Gemcitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 30, 2026, 6:29 AM EDT
Completed Phase 3 Interventional Results available

A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.

NCT00282464
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Placebo, Geodon (Ziprasidone)
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
43
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 30, 2026, 6:29 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes

NCT01273181
View directory record Official record
Conditions
Metastatic Cancer, Metastatic Renal Cancer, Metastatic Melanoma
Interventions
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes, Aldesleukin, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 30, 2026, 6:29 AM EDT
Completed Phase 1 Interventional

Study of Erlotinib and Metformin in Triple Negative Breast Cancer

NCT01650506
View directory record Official record
Conditions
Breast Cancer
Interventions
Metformin, Erlotinib
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 30, 2026, 6:29 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

NCT03041701
View directory record Official record
Conditions
Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal
Interventions
Dasatinib, Ganitumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Los Angeles, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 30, 2026, 6:29 AM EDT
Terminated Phase 2 Interventional Results available

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

NCT04430036
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
AGEN1884, AGEN2034, Cisplatin, Gemcitabine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 30, 2026, 6:29 AM EDT
Completed Not applicable Interventional

A Clinical Trial of Cognitive Multisensory Rehabilitation for Sensory and Motor Recovery in Adults With Spinal Cord Injury

NCT05167032
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Cognitive Multisensory Rehabilitation (CMR), Adaptive fitness
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 30, 2026, 6:29 AM EDT
Completed Phase 1 Interventional

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

NCT02631733
View directory record Official record
Conditions
Malignant Solid Neoplasm
Interventions
Ferumoxytol, Irinotecan Sucrosofate, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Veliparib
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
Baltimore, Maryland • Bethesda, Maryland • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 30, 2026, 6:29 AM EDT